Skip to content

5-MeO-DMT research published in 2023

28 studies whose primary subject is 5-MeO-DMT were published in 2023, up from 13 in 2022. Newest first. Back to the 5-MeO-DMT overview

Studies

Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice

Research Square December 28, 2023 Margareth Nogueira, Daiane C Ferreira Golbert, Richardson Menezes et al. 2 citations preprint

Abstract Serotonergic psychedelics have potential therapeutic effects in treating anxiety and mood disorders, often after a single dose, and are suggested to have plasticity-inducing action. One lesser studied psychedelic, the 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), is suggested to have anxiolytic effects yet a comprehensive mechanism of action is still lacking. Here, we investigated the...

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Psychopharmacology December 11, 2023 Haley Maria Dourron, Charles D. Nichols, Otto Simonsson et al. 23 citations

5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to those induced by epileptiform activity,...

DOI: 10.1007/s00213-023-06517-1 (opens in new tab) Full text (opens in new tab) 5-ht1a receptors Flashbacks Seizures Psychedelics hallucinogens +7

N, N-dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an in vitro investigation.

Xenobiotica December 1, 2023 Emma Eckernäs, Alicia Macan-Schönleben, Moa Andresen-Bergström et al. 6 citations

N, N-dimethyltryptamine (DMT) is a psychedelic compound that has shown potential in the treatment of depression. Aside from the primary role of monoamine oxidase A (MAO-A) in DMT metabolism, the metabolic pathways are poorly understood. Increasing this understanding is an essential aspect of ensuring safe and efficacious use of DMT.This work aimed to investigate the cytochrome 450 (CYP)...

DOI: 10.1080/00498254.2023.2278488 (opens in new tab) Full text (opens in new tab) N n-dimethyltryptamine Cytochrome p450 Human liver microsomes In vitro metabolism +6

The possible place for psychedelics in pharmacotherapy of mental disorders.

Pharmacological Reports December 1, 2023 Adam Wojtas 10 citations

Since its emergence in the 1960s, the serotonergic theory of depression bore fruit in the discovery of a plethora of antidepressant drugs affecting the lives of millions of patients. While crucial in the history of drug development, recent studies undermine the effectiveness of currently used antidepressant drugs in comparison to placebo, emphasizing the long time it takes to initiate the...

5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study

Frontiers in Psychiatry November 23, 2023 Anya Ragnhildstveit, Ryan Khan, Paul Seli et al. 17 citations

Psychedelic therapy is, arguably, the next frontier in psychiatry. It offers a radical alternative to longstanding, mainstays of treatment, while exciting a paradigm shift in translational science and drug discovery. There is particular interest in 5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT)—a serotonergic psychedelic—as a novel, fast-acting therapeutic. Yet, few studies have directly...

DOI: 10.3389/fpsyt.2023.1271152 (opens in new tab) Adverse effect Psychopathology Clinical psychology

A mechanistic insight for the biosynthesis of N,N-dimethyltryptamine: An ONIOM theoretical approach.

Biochemical and Biophysical Research Communications October 20, 2023 Lucas Pinheiro Coutinho, Sérgio Ruschi Bergamachi Silva, Pedro de Lima-Neto et al. 3 citations

Psychoactive natural products are potent serotonergic agonists capable of modulating brain functions such as memory and cognition. These substances have shown therapeutic potential for treating various mental disorders. The fact that N,N-dimethyltryptamine (DMT) is produced endogenously in several plants and animals, including humans, makes it particularly attractive. As an amino acid-derived...

DOI: 10.1016/j.bbrc.2023.08.043 (opens in new tab) Full text (opens in new tab) Mechanism N,N-Dimethyltryptamine DMT Oniom Psychoactives +4

Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework.

CPT: Pharmacometrics & Systems Pharmacology October 1, 2023 Emma Eckernäs, Jeroen Koomen, Christopher Timmermann et al. 1 citation

N,N-dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its short half-life, continuous infusion of DMT has been proposed to extend the psychedelic experience and potential therapeutic effects. The primary aim of this work was to design an infusion protocol for DMT based on a desired level of psychedelic...

DOI: 10.1002/psp4.13037 (opens in new tab) Full text (opens in new tab) Psychedelic-therapy DMT-Research Clinical-protocols Pharmacology +1

Molecular Docking, MM-GBSA, and Molecular Dynamics Approach: 5-MeO-DMT Analogues as Potential Antidepressants.

Archives of Razi Institute October 1, 2023 Rajagopal Kalirajan, Khare Rishabh, Jupudi Srikanth et al.

Since depression is a common mental illness affecting an estimated 5% of people worldwide, investigators are encouraged to develop effective antidepressants. According to the monoamine-deficiency hypothesis, the underlying pathophysiology of depression is a deficiency of some neurotransmitters (serotonin, norepinephrine, or dopamine) in the central nervous system. The neurotransmitter serotonin...

Discovery and In Vitro Characterization of SPL028: Deuterated N,N-Dimethyltryptamine.

ACS Medicinal Chemistry Letters September 14, 2023 Marie Layzell, Peter Rands, Meghan Good et al. 6 citations

The psychedelic N,N- dimethyltryptamine (DMT) is in clinical development for the treatment of major depressive disorder. However, when administered via intravenous infusion, its effects are short-lived due to rapid clearance. Here we describe the synthesis of deuterated analogues of DMT with the aim of prolonging the half-life and decreasing the clearance rate while maintaining similar...

DOI: 10.1021/acsmedchemlett.3c00143 (opens in new tab) Full text (opens in new tab) Psychedelics Drug development Mental health treatment Pharmaceutical research

Synthetic studies toward the marine alkaloid convolutindole A, a structurally remarkable derivative of the hallucinogen N,N-Dimethyltryptamine (DMT)

Tetrahedron Letters September 13, 2023 Karen Ichikawa, Jessica C. Neville, Yihan Yu et al. 3 citations

Herein we report the results of a synthetic strategy toward the marine alkaloid convolutindole A, a structurally remarkable derivative of the hallucinogen N,N-dimethyltryptamine (DMT). While attempts to forge an advanced tryptamine intermediate using the Fischer reaction were unsuccessful, an iterative C-H functionalisation strategy proved more fruitful. Subjecting 6-bromoindole to an...

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.

The American Journal of Drug and Alcohol Abuse September 3, 2023 Alan Kooi Davis, Yitong Xin, Nathan D. Sepeda et al. 29 citations

Background: Research in psychedelic medicine has focused primarily on civilian populations. Further study is needed to understand whether these treatments are effective for Veteran populations.Objectives: Here, we examine the effectiveness of psychedelic-assisted therapy among trauma-exposed Special Operations Forces Veterans (SOFV) seeking treatment for cognitive and mental health problems in...

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice.

Neuropsychopharmacology August 1, 2023 Sarah J. Jefferson, Ian Gregg, Mark Dibbs et al. 57 citations

Serotonergic psychedelics are gaining increasing interest as potential therapeutics for a range of mental illnesses. Compounds with short-lived subjective effects may be clinically useful because dosing time would be reduced, which may improve patient access. One short-acting psychedelic is 5-MeO-DMT, which has been associated with improvement in depression and anxiety symptoms in early phase...

All-natural 5-MeO-DMT sigma receptor 1 agonist and its therapeutic impact in mental and neurodegener-ative diseases through mitochondrial activation

Science Reviews Biology July 30, 2023 Milena Batalla 2 citations

The sigma-1 receptor S1R is a chaperone that resides mainly at the mitochondrion-associated endoplasmic reticulum ER membrane MAM, it is considered a “pluripotent modulator” in living systems, plays a critical role in maintaining neuronal homeostasis and acts as a dynamic pluripotent modulator in living systems. Given its specific localization at the MAM, S1R plays a major role regulating...

DOI: 10.57098/scirevs.biology.2.2.1 (opens in new tab) Sigma-1 receptor Epigenetics Mitochondrion Agonist +2

Neuromodulatory mechanisms of N,N-dimethyltryptamine

Brain Network and Modulation July 1, 2023 Javier Hidalgo Jiménez 2 citations

N,N-dimethyltryptamine (DMT) is the simplest psychedelic tryptamine and is produced naturally by many plant and animal species, including humans. While classical psychedelics, such as lysergic acid diethylamide, or psilocybin, are gaining interest because of their therapeutic potential, DMT has yet to be fully investigated. However, preliminary clinical evidence suggests that DMT and/or...

A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

Frontiers in Psychiatry June 20, 2023 Johannes T. Reckweg, Cees van Leeuwen, Cécile Henquet et al. 86 citations

Background Treatment-resistant depression (TRD) is a substantial public health burden, but current treatments have limited effectiveness. The aim was to investigate the safety and potential antidepressant effects of the serotonergic psychedelic drug 5-MeO-DMT in a vaporized formulation (GH001) in adult patients with TRD. Methods The Phase 1 part ( n = 8) of the trial investigated two single...

Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the "God Molecule".

Pharmaceuticals June 2, 2023 Ahmed Al-Imam, Marek A Motyka, Beata Hoffmann et al. 6 citations

Aboriginals of Latin America have used DMT (N,N-dimethyltryptamine) in ritualistic ceremonies for centuries. Nevertheless, there are limited data on web users' interest concerning DMT. We aim to review the literature and explore the spatial-temporal mapping of online search behavior concerning DMT, 5-MeO-DMT, and the Colorado River toad via Google Trends over the past 10 years (2012-2022) while...

DOI: 10.3390/ph16060831 (opens in new tab) Full text (opens in new tab) Incilius alvarius 5-Methoxy-N,N-Dimethyltryptamine Colorado river toad Sonoran desert toad +4

“In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E. coli”

Metabolic Engineering May 23, 2023 Lucas M. Friedberg, Abhishek K. Sen, Quynh Nguyen et al. 22 citations

N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and 5-hydroxy-N,N-dimethyltryptamine (bufotenine) are psychedelic tryptamines found naturally in both plants and animals and have shown clinical potential to help treat mental disorders, such as anxiety and depression. Advances in both metabolic and genetic engineering make it possible to engineer microbes as cell...

DOI: 10.1016/j.ymben.2023.05.006 (opens in new tab) Tryptamine Escherichia coli Fermentation Metabolic engineering +3

Pharmacokinetics of N,N-dimethyltryptamine in Humans.

European Journal of Drug Metabolism and Pharmacokinetics May 1, 2023 Meghan Good, Zelah Joel, Tiffanie Benway et al. 54 citations

N,N-dimethyltryptamine (DMT) is a psychedelic compound under development for the treatment of major depressive disorder (MDD). This study evaluated the preclinical and clinical pharmacokinetics and metabolism of DMT in healthy subjects. The physiochemical properties of DMT were determined using a series of in vitro experiments and its metabolic profile was assessed using monoamine oxidase (MAO)...

DOI: 10.1007/s13318-023-00822-y (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Pharmacology Drug metabolism

Orally Active Forms of DMT, 5-MeO-DMT, and Long-Acting MDMA for the Treatment of Neuropsychiatric Disorders.

ACS Medicinal Chemistry Letters April 13, 2023 Robert B. Kargbo 4 citations

This Patent Highlight describes derivatives of DMT, 5-MeO-DMT, and MDMA that are metabolically converted to biologically active analogs. When these prodrugs are administered to a subject, they potentially could be used therapeutically in conditions associated with neurological diseases. Furthermore, the disclosure provides methods to potentially treat conditions comprising major depressive...

DOI: 10.1021/acsmedchemlett.3c00077 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment Drug development Therapeutic compounds

Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice

ACS Pharmacology & Translational Science March 10, 2023 Marilyn Naeem, Grant C. Glatfelter, Duyen N. K. Pham et al. 25 citations

Analogues of 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin) are being sold on recreational drug markets and developed as potential medications for psychedelic-assisted therapies. Many of these tryptamine-based psilocybin analogues produce psychedelic-like effects in rodents and humans primarily by agonist activity at serotonin 2A receptors (5-HT2A). However, the comprehensive...